

What Is Claimed Is:

1. A method of treating a patient having hemophilia B comprising administering to said patients a hemophilia B symptom preventing or ameliorating amount of Factor IX produced by the non-human transgenic mammal and a pharmaceutically acceptable carrier.
2. A method of claim 1, wherein said Factor IX is biologically active human Factor IX.
3. A method of claim 1, wherein said non-human transgenic mammal is selected from the group consisting of mice, rats, rabbits, pigs, sheep, goats and cows.
4. A method of claim 3, wherein said non-human transgenic mammal is a pig and secretes biologically active human Factor IX per milliliter of milk.
5. A method of claim 2, wherein said biologically active human Factor IX has a specific activity that is at least about 5-200% greater than the specific activity of human Factor IX isolated from human plasma.
6. A method of claim 5, wherein said non-human transgenic mammal is a pig.
7. A method of claim 2, wherein said amount of said human Factor IX that is administered comprises about 18-30 IU/kg administered once a week.
8. A method of claim 2, wherein said administration of said human Factor IX raises Factor IX levels 20% or greater in the blood.
9. A biologically active human Factor IX produced in a non-human transgenic mammal, said Factor IX comprising a specific activity that is at least about 5-200% greater than the specific activity of human Factor IX isolated from human plasma.
10. A biologically active human Factor IX of claim 9, wherein said non-human transgenic mammal is a pig.